 |
Prospector
Profile
07.1648
|
| |
| Neurologix, Inc. |
NAICS |
541710 |
| One Bridge Plaza
Fort Lee, NJ 07024 |
Description |
Biotechnology |
| (201) 592-6451 |
Employees |
8 |
| http://www.neurologix.net/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-10.3750 |
| |
Assets |
(mil) |
11.5800 |
| |
Liability |
(mil) |
0.7290 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Neurologix, Inc. had a net loss of $5.9 million for the nine months ended September 30, 2007, substantially lower than the $8.69 million net loss reported during the nine months ended September 30, 2006. For the three months ended September 30, 2007, the Company had a $1.91 million net loss, much lower than the $2.77 net loss incurred during the three months ended September 30, 2006. As a result of its recurring losses, the Company has an accumulated deficit of $28.78 million as of September 30, 2007.
|
| |
|
Intellectual Property:
The Company believes that its success depends upon its ability to develop and protect proprietary products and technology. Accordingly, the Company applies for U.S. patents covering those developments that are innovative, technologically significant and commercially attractive to its field of operations. At present, it holds the exclusive license to 4 issued U.S. patents, 8 pending U.S. patent applications, 7 pending foreign patent applications and 1 issued foreign patent. In addition, the Company owns 1 issued U.S. patent and 8 U.S. pending patent applications covering gene therapy technologies and 2 non-exclusive licenses to U.S. patents covering delivery mechanisms for gene therapy. The exclusive patent licenses were granted by Rockefeller University and Thomas Jefferson University, pursuant to research agreements which the Company had with these institutions. The non-exclusive licenses were granted pursuant to agreements the Company has with Rockefeller University, Yale University and Diamyd Therapeutics AB. [SEC Filing 10-KSB 04-02-07]
|
| |
|
Description:
The Company engages in the research and development of treatments for disorders of the brain and central nervous system primarily utilizing gene therapies.
|
| |
|
Officers:
John E. Mordock (Pres., CEO & Dir.); Marc L. Panoff (CFO & Treas.); Christine V. Sapan (EVP & Chief Development Officer)
|
| |
|
Auditor:
JH Cohn LLP
|
| |
|
Securities:
Common Stock-Symbol NRGX.OB; OTC BB;
26,892,976 common shares outstanding as of November 6, 2007.
|
| |
| |
| |
| return to main page |
|
|
